Systematic evalution of Fuzheng Huayu Capsule combined with Adefovir Dipivoxil in treatment of chronic hepatitis B with hepatic fibrosis / 中草药

ABSTRACT

To systemically review the efficacy and safety of Fuzheng Huayu Capsule (FHC) combined with Adefovir Dipivoxil in treatment of chronic hepatitis B with hepatic fibrosis. Wanfang, CNKI, VIP, CBM, PubMed, Cochrane and Embase were retrieved by computers to collect the RCTs of FHC combined with Adefovir Dipivoxil in treatment of chronic hepatitis B with hepatic fibrosis from their inception to March 2017. After two reviewers separately screened literature according to the inclusion and exclusion criteria, extracted data and assessed the quality of the included studies, data were analyzed with RevMan 5.3 sofware. Totally 14 RCTs were included with 1 400 patients involved. According to Meta-analysis, compared with Adefovir Dipivoxil alone, FHC combined with Adefovir Dipivoxil was more efficiently in reducing the liver fibrosis indexes HA [MD = -99.66, CI = -129.94 - -69.37], P < 0.000 01]; LN [MD = -40.99, CI = -58.56 - -23.41, P < 0.000 01]; PCIII [MD = -76.40, CI = -108.15 - -44.66, P < 0.000 01]; IV-C [MD = -55.24, CI = -79.19 - -31.29, P < 0.000 01], in improving the liver function ALT [MD = -21.05, CI = -22.58 - -19.52, P < 0.000 01]; AST [MD = -16.74, CI = -25.14 - -8.33, P < 0.000 1]; TBIL [MD = -10.38, CI = 14.17 - 6.59, P < 0.000 01]; ALB [MD = 4.35, CI = -3.48 - 5.23, P < 0.000 01], and improving the ultrasound imaging results. Also, no significant adverse reaction was reported. FHC combined with Adefovir Dipivoxil could significantly improve liver function, reduce liver fibrosis indexes, and had less adverse reactions, but more large sample, high quality clinical trial are required to verify the curative effect.